Lipid disorders in chronic kidney disease: Reverse epidemiology and therapeutic approach

Journal of Nephrology

Volumn 21, Issue 5, 2008, Pages 635-644

  Chmielewski, Michael ^a,b   Carrero, Juan Jesus ^a   Nordfors, Louise ^a   Lindholm, Bengt ^a   Stenvinkel, Peter ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Chronic kidney disease; Dyslipidemia; Mendelian randomization; Reverse epidemiology

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CD36 ANTIGEN; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTER TRANSFER PROTEIN; CHYLOMICRON; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SCAVENGER RECEPTOR A; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN RECEPTOR; ANTILIPEMIC AGENT;

ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIET RESTRICTION; DRUG EFFICACY; DRUG TARGETING; DYSLIPIDEMIA; ENZYME ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE; LIFESTYLE MODIFICATION; MORTALITY; NEPHROTIC SYNDROME; REVIEW; SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; CHRONIC DISEASE; KIDNEY DISEASE; LIPID METABOLISM; METABOLISM; PATHOPHYSIOLOGY; RISK REDUCTION;

ANTILIPEMIC AGENTS; CHRONIC DISEASE; DYSLIPIDEMIAS; HUMANS; KIDNEY DISEASES; LIPID METABOLISM; RISK REDUCTION BEHAVIOR;

EID: 58849123524     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(Suppl 3):S112-S119.
2. Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006;17:2034-2047.
3. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361:2024-2031.
4. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238-248.
5. Rutkowski B, Chmielewski M. Mechanisms of lipid disturbances in chronic renal failure. In: Andreoli TE, Ritz E, Rosivall L, eds. Nephrology, hypertension, dialysis, transplantation. Budapest: Hungarian Kidney Foundation; 2005:467-476.
6. Dautin G, Soltani Z, Ducloux D, et al. Hemodialysis reduces plasma apolipoprotein C-1 concentration making VLDL a better substrate for lipoprotein lipase. Kidney Int. 2007;72:871-878.
7. Molitch ME. Management of dyslipidemias in patients with diabetes and chronic kidney disease. Clin J Am Soc Nephrol. 2006;1:1090-1099.
8. Prichard SS. Management of hyperlipidemia in patients on peritoneal dialysis: current approaches. Kidney Int Suppl. 2006;103:S115-S117.
9. Bagdade JD, Yee E, Wilson DE, Shafrir E. Hyperlipidemia in renal failure: studies of plasma lipoproteins, hepatic triglyceride production, and tissue lipoprotein lipase in a chronically uremic rat model. J Lab Clin Med. 1978;91:176-186.
10. Szolkiewicz M, Nieweglowski T, Korczynska J, et al. Upregulation of fatty acid synthase gene expression in experimental chronic renal failure. Metabolism. 2002;51:1605-1610.
11. Rutkowski B, Szolkiewicz M, Korczynska J, et al. The role of lipogenesis in the development of uremic hyperlipidemia. Am J Kidney Dis. 2003;41(Suppl 1):S84-S88.
12. Bagdade J, Porte D, Biermann E. Hypertriglyceridemia: a metabolic consequence of chronic renal failure. N Engl J Med. 1968;279:181-185.
13. Vaziri ND, Liang K. Down-regulation of VLDL receptor expression in chronic experimental renal failure. Kidney Int. 1997;51:913-919.
14. Kim C, Vaziri ND. Down-regulation of hepatic LDL receptorrelated protein (LRP) in chronic renal failure. Kidney Int. 2005;67:1028-1032
15. Chmielewski M, Nieweglowski T, Swierczynski J, Rutkowski B, Boguslawski W. Diurnal rhythm of cholesterol biosynthesis in experimental chronic renal failure. Mol Cell Biochem. 2001;228:33-37.
16. Chmielewski M, Sucajtys E, Swierczynski J, Rutkowski B, Boguslawski W. Contribution of increased HMG-CoA reductase gene expression to hypercholesterolemia in experimental chronic renal failure. Mol Cell Biochem. 2003;246:187-191.
17. Chmielewski M, Sucajtys-Szulc E, Kossowska E, Swierczynski J, Rutkowski B, Boguslawski W. Increased gene expression of liver SREBP-2 in experimental chronic renal failure. Atherosclerosis. 2007;191:326-332.
18. O'Neal D, Lee P, Murphy B, Best J. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis. 1996;27:84-91.
19. Prichard SS. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol. 2003;14(Suppl 4):S315-320.
20. Ando M, Lundkvist I, Bergstrom J, Lindholm B. Enhanced scavenger receptor expression in monocyte-macrophages in dialysis patients. Kidney Int. 1996;49:773-780.
21. Ando M, Gafvels M, Bergstrom J, Lindholm B, Lundkvist I. Uremic serum enhances scavenger receptor expression and activity in the human monocytic cell line U937. Kidney Int. 1997;51:785-792.
22. Chmielewski M, Bryl E, Marzec L, Aleksandrowicz E, Witkowski JM, Rutkowski B. Expression of scavenger receptor CD36 in chronic renal failure patients. Artif Organs. 2005;29:608-614.
23. Ruan XZ, Varghese Z, Powis SH, Moorhead JF. Dysregulation of LDL receptor under the influence of inflammatory cytokines: a new pathway for foam cell formation. Kidney Int. 2001;60:1716-1725.
24. Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-alpha: central factors in the alfered cytokine network of uremia - the good, the bad, and the ugly. Kidney Int. 2005;67:1216-1233.
25. De Sain-Van Der Velden MG, Reijngou.d DJ, Kaysen GA, et al. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol. 1998;9:1474-1481.
26. Vaziri ND. Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int. 2003;63:1064-1976.
27. de Sain-van der Velden MG, Kaysen GA, Barrett HA, et al. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Int. 1998;53:994-1001.
28. Kisielnicka E, Zdrojewski Z, Wroblewska M, Kortas B. Rutkowski B. Lipid disturbances in a two-year follow-up after successful kidney transplantation. Transplant Proc. 2000;32:1358-1362.
29. Guijarro C, Massy ZA, Kasiske BL. Clinical correlation between renal allograft failure and hyperlipidemia. Kidney Int Suppl. 1995;52:S56-59.
30. Fellstrom B. Impact and management of hyperlipidemia posttransplantation. Transplantation. 2000;70(11 Suppl):SS51-57.
31. Chmielewski M, Zdrojewski Z, Rutkowski B. Benefits and menaces related to the use of statins in patients after renal transplantation. Ann Transplant. 2002;7:6-10.
32. Guarnieri GF, Moracchiello M, Campanacci L, et al. Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia. Kidney Int Suppl. 1978;8:S26-30.
33. McLeod R, Reeve CE, Frohlich J. Plasma lipoprotains and lecithin:cholesterol acyltransferase distribution in patients on dialysis. Kidney Int. 1984;25:683-688.
34. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2006;290:F262-272.
35. Dantoine TF, Debord J, Charmes JP, et al. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol. 1998:2082-2088.
36. Morena M, Crisiol JP, Dantoine T, Carbonneau MA, Descomps B, Canaud B. Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients. Nephrol Dial Transplant. 2000; 15:389-395.
37. Stenvinkel P, Heimbürger O, Tuck CH, Berglund L. Apo(a)isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int. 1998;53:1336-1342.
38. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation. 1992;86:475-482.
39. Stenvinkel P, Berglund L, Heimbürger O, Pettersson E, Alvestrand A. Lipoprotein(a) in nephrotic syndrome. Kidney Int. 1993;44:1116-1123.
40. Kronenberg F, Konig P, Neyer U, et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1995;6:110-120.
41. Heimbürger O, Stenvinkel P, Berglund L, Tranoeus A, Lindholm B. Increased plasma, lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. Nephron. 1996;72:135-144.
42. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol. 2005; 16:529-538.
43. Tschope W, Koch M, Thomas B, Ritz E. Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Results of a prospective study. The German Study Group Diabtes and Uremia. Nephron. 1993;64:354-358.
44. Nishizawa Y, Shoji T, Kakiya R, et al. Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int Suppl. 2003;84:S117-120.
45. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208-2218.
46. Degoulet P, Legrain M, Reach I, et al. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane Collaborative Study. Nephron. 1982;31:103-110.
47. Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005;293:1737-1745.
48. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458-482.
49. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. 2002;61:1887-1893.
50. Hocher B, Ziebig R, Altermann CU, et al. Different impact of biomarkers as mortality predictors among diabetic and non-diabetic patients undergoing hemodialysis. J Am Soc Nephrol. 2003; 14:2329-2337.
51. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004;291:451-459.
52. Chiang CK, Ho TI, Hsu SP, et al. Low-density lipoprotein cholesterol: association with mortality and hospitalization in hemodialysis patients. Blood Purif. 2005;23:134-140.
53. Habib AN, Baird BC, Leypoldt JK, Cheung AK, Goldfarb-Rumyantzev AS. The association of lipid levels with mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant. 2006;21:2881-2892.
54. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol. 2007;18:304-311.
55. Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K, Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol. 2007;18:293-303.
56. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63:793-808.
57. Flegel WA, Baumstark MW, Weinstock C, Berg A, Northoff H. Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-1. Infect Immun. 1993;61:5140-5146.
58. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A. 1993;90:12040-12044.
59. Read TE, Grunfeld C, Kumwenda ZL, et al. Triglyceride-rich lipoproteins prevent septic death in rats. J Exp Med. 1995;182:267-272.
60. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet. 2000;356:930-933.
61. Marshall CJ. Protein prenylation: a mediator of protein-protein interactions. Science. 1993;259:1865-1866.
62. Chmielewski M, Rutkowski B. Mechanisms of statin nephro-protective actions. In: Benhagen EF, ed. Hypertension: new research. New York: Nova; 2005:239-262.
63. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58:293-301.
64. Samuelsson O, Attman PO, Knight-Gibson C, et al. Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol. 1998;9:1482-1488.
65. Ozsoy RC, van der Steeg WA, Kastelein JJ, Arisz L, Koopman MG. Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin. Nephrol Dial Transplant. 2007;22:15?8-1586.
66. Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14:2084-2091.
67. Massy ZA, Nguyen Khoa T, Lacour B, Descamps-Latscha B, Man NK, Jungers P. Dyslipidaemia and the progression of renal disease in chronic renal failure patients. Nephrol Dial Transplant. 1999;14:2392-2397.
68. European best practice guidelines for renal transplantation: Section IV: long-term management of the transplant recipient. IV.5.3. cardiovascular risks: hyperlipidaemia. Nephrol Dial Transplant. 2002;17(Suppl 4):26-28.
69. National Kidney Foundation. NKF-K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis. 2003;41 (Suppl 3):S1-S91.
70. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis. 2001;37:484-489.
71. Harris K, Thomas M, Short C, Moore R. Assessment of the efficiency of treatment of dyslipidaemia in renal outpatients. J Nephrol. 2002;15:263-269.
72. Kok FJ, Kromhout D. Atherosclerosis: epidemiological studies on the health effects of a Mediterranean diet. Eur J Nutr.2 2004;43(Suppl 1):2-5.
73. Stenvinkel P, Elinder CG, Barany P. Physical activity promotes health also among dialysis patients. Int J Cardiol. 2000;72:299-300.
74. Rutkowski P, Klassen A, Sebekova K, Bahner U, Heidland A. Renal disease in obesity: the need for greater attention. J Ren Nutr. 2006;16:216-223.
75. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002;61:297-304.
76. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-2261.
77. Holdaas H, Fellström B, Jardine AG, et al. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant. 2005;20:974-980.
78. Wanner C, Drechsler C, Krane V. Lipid metabolism in chronic kidney disease: the role of statins in cardiovascular risk. J Ren Nutr. 2007;17:75-78.
79. Ruan XZ, Chen Y, Powis SH, Ma K, Moorhead JIF, Varghese Z. Inflammation causes statin resistance: a potential mechanism for ineffectiveness of statin therapy in patients with chronic inflammation [abstract]. J Am Soc Nephrol. 2007;18:91A.
80. Stenvinkel P, Rodriguez-Ayala E, Massy ZA, et al. Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2006;1:281-287.
81. Tonelli M, Isles C, Gurhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110:1557-1563.
82. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl. 2003;84:S207-S210.
83. Fellstrom BC, Holdaas H, Jardine AG. Why do we need a statin trial in hemodialysis patients? Kidney Int Suppl. 2003;84:S204-206.
84. Wilkes BM, Reiner D, Kern M, Burke S. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clin Nephrol. 1998;50:381-386.
85. Rip J, Nierman MC, Ross CJ, et al. Lipoprotein lipase S447X: a n aturally occurring gain-of-function mutation. Arterioscler Thromb Vasc Biol. 2006;26:1236-1245.
86. Fan Y, Laaksonen R, Janatuinen T, et al. Hepatic lipase gene variation is related to coronary reactivity in healthy young men. Eur J Clin Invest. 2001;31:574-580.
87. McCaskie PA, Cadby G, Hung J, et al. The C-480T hepatic lipase polymorphism is associated with HDL-C but not with risk of coronary heart disease. Clin Genet. 2006;70:114-121.
88. Vedie B, Jeunemaitre X, Megnien JL, Atger V, Simon A, Moatti N. A new DNA polymorphism in the, 5′ untranslated region of the human SREBP-1 a is related to development of atherosclerosis in high cardiovascular risk population. Atherosclerosis. 2001;154:589-597.
89. Robinet P, Vedie B, Chironi G, et al. Characterization of polymorphic structure of SREBP-2 gene: role in atherosclerosis. Atherosclerosis. 2003;168:381-387.
90. Mangravite LM, Thorn CF, Krauss RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J. 2006;6:360-374.
91. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol. 2002;155:487-495.
92. Eggertsen G, Heimbürger O, Stenvinkel P, Berglund L. Influence of variation at the apolipoprotein E locus on lipid and lipoprotein levels in CAPD pratients. Nephrol Dial Transplant. 1997;12:141-144.
93. Liberopoulos EN, Miltiadous GA, Cariolou M, Tselepis AD, Siamopoulos KC, Elisaf MS. The influence of serum apolipoprotein E concentration and polymorphism on serum lipid parameters in hemodialysis patients. Am J Kidney Dis. 2004;44:300-308.
94. Horita K, Eto M. Makino I. Apolipoprotein E2, renal failure and lipid abnormalities in non-insulion-dependent diabetes mellitus. Atherosclerosis. 1994;107:203-211.
95. Werle E, Fiehn W, Hasslacher C. Apolipoprotein E polymorphism and renal function in German type 1 and type 2 diabetic patients. Diabetes Care. 1998;21:994-998.
96. Oda H, Yorioka N, Ueda C, Kushihata S, Yamakido M. Apolipoprotein E polymorphism and renal disease. Kidney Int Suppl. 1999;71:S25-S27.
97. Yorioka N, Nishida Y, Oda H, Watanabe T, Yamakido M. Apolipoprotein E polymorphism in IgA nephropathy. Nephron. 1999;83:246-249.
98. Araki S, Moczulski DK, Hanna L, Scott LJ, Warram JH, Krolewski AS. APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based studies. Diabetes. 2000;49:2190-2195.
99. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1-22.
100. Katan MB. Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet. 1986;1:507-508.
101. Zoccali C, Testa A, Spoto B, Tripepi G, Mallamaci F. Mendelian randomization: a new approach to studying epidemiology in ESRD. Am J Kidney Dis. 2006;47:332-341.
102. Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol. 2004;33:30-42.